Cryoport Systems Wins Best Cell & Gene Therapy Supplier Award at APCGTEA 2025

Cryoport Systems is proud to announce that we have been awarded Best Cell & Gene Therapy Supplier – Cell Processing Systems at the 2025 Asia-Pacific Cell & Gene Therapy Excellence Awards (APCGTEA).  

This recognition is especially meaningful because it was determined by votes from more than 10,000 professionals across the global cell and gene therapy community. To be selected as a winner in this competitive category reflects both the trust of our clients and partners and the tireless commitment of our teams worldwide.  

A Milestone for Innovation and Partnership 

The APCGTEA Awards celebrate organizations and leaders who are advancing the cell and gene therapy field through innovation and impact. Winning this award acknowledges our work in developing and delivering robust solutions for cell processing systems that ensure product integrity and compliance throughout the therapy lifecycle.  

At Cryoport Systems, we see this achievement not only as a recognition of past success, but as a call to continue raising the standard of excellence in supply chain solutions for advanced therapies. Our focus remains on enabling scalability, reducing risk, and providing the industry’s most robust, advanced solutions that empower developers to deliver transformative treatments to patients worldwide.  

We extend our heartfelt thanks to our clients, collaborators, and colleagues across the industry who supported our nomination and cast their votes. This award belongs to all of you as much as it does to us. It reflects the strength of our partnerships and the shared mission we pursue together, to Enable the Outcome™ for every therapy, every time.  

As the advanced therapies landscape continues to evolve, we remain committed to investing in innovation, strengthening our global infrastructure, and delivering the certainty required to bring these life-changing therapies to patients in need.  

We are honored by this recognition and inspired to keep building the future of cell and gene therapy logistics.